Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 901–1,000 of 1,082
Targeted Nanoparticles for Colorectal Cancer
Cisterna, B. A., Kamaly, N., Choi, W. I., Tavakkoli, A., Farokhzad, O. C., & Vilos, C. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0194 · Cited by 166
O'Dwyer, P. J., & Catalano, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3031 · Cited by 166
Pelz, J. O. W., Stojadinovic, A., Nissan, A., Hohenberger, W., & Esquivel, J. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21169 · Cited by 165
VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Cowey, C. L., & Rathmell, W. K. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0015-5 · Cited by 165
Ladabaum, U., & Mannalithara, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.06.003 · Cited by 164
Federico, S. M., McCarville, M. B., Shulkin, B. L., Sondel, P. M., Hank, J. A., Hutson, P., Meagher, M., Shafer, A., Ng, C. Y., Leung, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0379 · Cited by 162
Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers
Singh, A. K., Kumar, R., & Pandey, A. K. (2018) · Current Chemical Genomics and Translational Medicine · doi:10.2174/2213988501812010009 · Cited by 165
Costa, R. A., Jorge, R., Calucci, D., Cardillo, J. A., Melo, L. A. S., & Scott, I. U. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0433 · Cited by 165
A review on pro- and anti-angiogenic factors as targets of clinical intervention
BOUIS, D., KUSUMANTO, Y., MEIJER, C., MULDER, N., & HOSPERS, G. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2005.10.006 · Cited by 165
Hurwitz, H. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.s.010 · Cited by 165
Self-citationEGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment
Press, M. F., & Lenz, H.-J. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 163
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
‘Liver First’ Approach in the Treatment of Colorectal Cancer with Synchronous Liver Metastases
Mentha, G., Roth, A. D., Terraz, S., Giostra, E., Gervaz, P., Andres, A., Morel, P., Rubbia-Brandt, L., & Majno, P. E. (2008) · Digestive Surgery · doi:10.1159/000184734 · Cited by 165
Yang, X., Zhang, Y., Hosaka, K., Andersson, P., Wang, J., Tholander, F., Cao, Z., Morikawa, H., Tegnér, J., Yang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503500112 · Cited by 161
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Okines, A., Puerto, O. D., Cunningham, D., Chau, I., Van Cutsem, E., Saltz, L., & Cassidy, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605259 · Cited by 163
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.200918462104c · Cited by 163
Henriksson, R., Asklund, T., & Poulsen, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0565-x · Cited by 162
Van Cutsem, E., Bajetta, E., Valle, J., Köhne, C.-H., Randolph Hecht, J., Moore, M., Germond, C., Berg, W., Chen, B.-L., Jalava, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5436 · Cited by 163
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Tam, B. Y. Y., Wei, K., Rudge, J. S., Hoffman, J., Holash, J., Park, S.-K., Yuan, J., Hefner, C., Chartier, C., Lee, J.-S., et al. (2006) · Nature Medicine · doi:10.1038/nm1428 · Cited by 163
Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy
Micke, P., & Östman, A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1217 · Cited by 162
Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab
Ellis, L. M., Curley, S. A., & Grothey, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.754 · Cited by 163
First-line chemotherapy for mCRC—a review and evidence-based algorithm
Cremolini, C., Schirripa, M., Antoniotti, C., Moretto, R., Salvatore, L., Masi, G., Falcone, A., & Loupakis, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.129 · Cited by 162
Lewandowski, R. J., Thurston, K. G., Goin, J. E., Wong, C.-Y. O., Gates, V. L., Buskirk, M. V., Geschwind, J.-F. H., & Salem, R. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000179815.44868.66 · Cited by 162
Angiogenesis as a strategic target for ovarian cancer therapy
Spannuth, W. A., Sood, A. K., & Coleman, R. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1051 · Cited by 162
Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., Fahey, F., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not154 · Cited by 163
Franco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A. M., Brown, A. S., Hicklin, D. J., Foster, F. S., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3295 · Cited by 162
Arkenau, H.-T., Arnold, D., Cassidy, J., Diaz-Rubio, E., Douillard, J.-Y., Hochster, H., Martoni, A., Grothey, A., Hinke, A., Schmiegel, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7759 · Cited by 162
Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., & Sullivan, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx110 · Cited by 162
Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
HAN, E., & MONK, B. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.038 · Cited by 163
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
Reardon, D. A., Turner, S., Peters, K. B., Desjardins, A., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Jones, L. W., Kirkpatrick, J. P., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0038 · Cited by 161
Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161
Kammula, U. S., Kuntz, E. J., Francone, T. D., Zeng, Z., Shia, J., Landmann, R. G., Paty, P. B., & Weiser, M. R. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.07.007 · Cited by 160
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Mitchell, A., Adams, L. A., MacQuillan, G., Tibballs, J., vanden Driesen, R., & Delriviere, L. (2008) · Liver Transplantation · doi:10.1002/lt.21417 · Cited by 162
McCahill, L. E., Yothers, G., Sharif, S., Petrelli, N. J., Lai, L. L., Bechar, N., Giguere, J. K., Dakhil, S. R., Fehrenbacher, L., Lopa, S. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4044 · Cited by 163
Self-citationA review on angiogenesis and its assays.
Tahergorabi, Z., & Khazaei, M. (2012) · PubMed Central · Cited by 237
Maroun, J. A., Anthony, L. B., Blais, N., Burkes, R., Dowden, S. D., Dranitsaris, G., Samson, B., Shah, A., Thirlwell, M. P., Vincent, M. D., et al. (2007) · Current Oncology · doi:10.3747/co.2007.96 · Cited by 161
Al-Samkari, H., Kasthuri, R. S., Parambil, J. G., Albitar, H. A., Almodallal, Y. A., Vázquez, C., Serra, M. M., Dupuis-Girod, S., Wilsen, C. B., McWilliams, J. P., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.261859 · Cited by 158
Repeat hepatectomy for recurrent colorectal metastases
Wicherts, D. A., de Haas, R. J., Salloum, C., Andreani, P., Pascal, G., Sotirov, D., Adam, R., Castaing, D., & Azoulay, D. (2013) · British Journal of Surgery · doi:10.1002/bjs.9088 · Cited by 158
Cassidy, J., Saltz, L. B., Giantonio, B. J., Kabbinavar, F. F., Hurwitz, H. I., & Rohr, U.-P. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0712-3 · Cited by 160
Self-citationAnti‐angiogenic drugs: from bench to clinical trials
Quesada, A. R., Muñoz‐Chápuli, R., & Medina, M. A. (2006) · Medicinal Research Reviews · doi:10.1002/med.20059 · Cited by 159
The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R., & Carmeliet, P. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.009 · Cited by 159
Zehetner, C., Kirchmair, R., Huber, S., Kralinger, M. T., & Kieselbach, G. F. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302451 · Cited by 159
Attar, A., Malka, D., Sabaté, J. M., Bonnetain, F., Lecomte, T., Aparicio, T., Locher, C., Laharie, D., Ezenfis, J., & Taieb, J. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.670743 · Cited by 159
Golfinopoulos, V., Salanti, G., Pavlidis, N., & Ioannidis, J. P. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70281-4 · Cited by 159
Urgent Need for a New Staging System in Advanced Colorectal Cancer
Poston, G. J., Figueras, J., Giuliante, F., Nuzzo, G., Sobrero, A. F., Gigot, J.-F., Nordlinger, B., Adam, R., Gruenberger, T., Choti, M. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6453 · Cited by 159
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
Homsi, J., & Daud, A. I. (2007) · Cancer Control · doi:10.1177/107327480701400312 · Cited by 160
Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets
Alghisi, G. C., & Rüegg, C. (2006) · Endothelium · doi:10.1080/10623320600698037 · Cited by 159
Klinger, M., Eipeldauer, S., Hacker, S., Herberger, B., Tamandl, D., Dorfmeister, M., Koelblinger, C., Gruenberger, B., & Gruenberger, T. (2009) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2008.12.013 · Cited by 158
Treatment for Pancreatic Cancer: Current Therapy and Continued Progress
Lockhart, A. C., Rothenberg, M. L., & Berlin, J. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.039 · Cited by 158
Self-citationNogué, M., Salud, A., Vicente, P., Arriví, A., Roca, J. M., Losa, F., Ponce, J., Safont, M. J., Guasch, I., Moreno, I., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0285 · Cited by 158
Wood, L. M., & Paterson, Y. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 157
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Self-citationAntineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
Varricchi, G., Ameri, P., Cadeddu, C., Ghigo, A., Madonna, R., Marone, G., Mercurio, V., Monte, I., Novo, G., Parrella, P., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00167 · Cited by 158
Toor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
Long-Term Survival After Repeated Resection of Pulmonary Metastases From Colorectal Cancer
Welter, S., Jacobs, J., Krbek, T., Krebs, B., & Stamatis, G. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.03.028 · Cited by 158
Huerta, S., Goulet, E. J., & Livingston, E. H. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2005.11.009 · Cited by 158
Beaudry, P., Force, J., Naumov, G. N., Wang, A., Baker, C. H., Ryan, A., Soker, S., Johnson, B. E., Folkman, J., & Heymach, J. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2271 · Cited by 158
Repeat Hepatectomy for Recurrent Colorectal Metastases
Kin, T., Nakajima, Y., Kanehiro, H., Hisanaga, M., Ohyama, T., 西尾, 和., Sho, M., 長尾, 美., & Nakano, H. (1998) · World Journal of Surgery · doi:10.1007/s002689900522 · Cited by 159
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
Marín, J. J. G., de Medina, F. S., Castaño, B., Bujanda, L., Romero, M. R., Martínez‐Augustin, O., del Moral-Ávila, R., & Briz, Ó. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.638303 · Cited by 169
Pulitanò, C., Bodingbauer, M., Aldrighetti, L. A., Jong, M. C. D., Castillo, F., Schulick, R. D., Parks, R. W., Choti, M. A., Wigmore, S. J., Gruenberger, T., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1459-4 · Cited by 167
Goldstein, D. A., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4904 · Cited by 165
O’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0731 · Cited by 167
Self-citationSun, Y., Chen, W., Torphy, R. J., Yao, S., Zhu, G., Lin, R., Lugano, R., Miller, E. N., Fujiwara, Y., Bian, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8922 · Cited by 174
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 205
Kornmann, M., Schwabe, W., Sander, S., Kron, M., Sträter, J., Polat, S., Kettner, E., Weiser, H. F., Baumann, W., Schramm, H., et al. (2003) · PubMed · Cited by 157
Takagawa, R., Fujii, S., Ohta, M., Nagano, Y., Kunisaki, C., Yamagishi, S., Osada, S., Ichikawa, Y., & Shimada, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0168-8 · Cited by 168
Microenvironment and Radiation Therapy
Yoshimura, M., Itasaka, S., Harada, H., & Hiraoka, M. (2013) · BioMed Research International · doi:10.1155/2013/685308 · Cited by 156
Flenniken, M. L., Willits, D. A., Harmsen, A. L., Liepold, L. O., Harmsen, A. G., Young, M., & Douglas, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.11.007 · Cited by 157
Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., Ruscelli, S., Mucciarini, C., Lorusso, V., Ragazzini, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv130 · Cited by 176
Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
Nagy, J. A., & Dvorak, H. F. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9500-6 · Cited by 156
McNeel, D. G., Eickhoff, J., Lee, F. T., King, D. M., Alberti, D., Thomas, J. P., Friedl, A., Kolesar, J., Marnocha, R., Volkman, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0262 · Cited by 156
NGUYEN, Q., SHAH, S., Hafiz, G., Quinlan, E., SUNG, J., CHU, K., Cedarbaum, J. M., & Campochiaro, P. A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.055 · Cited by 157
Anti-cancer therapies targeting the tumor stroma
Hofmeister, V., Schrama, D., & Becker, J. C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0365-5 · Cited by 169
Cutsem, E. V., Siena, S., Humblet, Y., Canon, J.-L., Maurel, J., Bajetta, E., Neyns, B., Kotasek, D., Santoro, A., Scheithauer, W., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm399 · Cited by 164
Role of Notch signaling in colorectal cancer
Qiao, L., & Wong, B. C. Y. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp236 · Cited by 154
The Gastrointestinal Tumor Microenvironment
Quante, M., Varga, J., Wang, T. C., & Greten, F. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.052 · Cited by 151
Kornprat, P., Jarnagin, W. R., Gönen, M., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & D'Angelica, M. I. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9068-y · Cited by 160
Koh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 166
Hazel, G. A. V., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M. J., Price, D., Bower, G., Briggs, G. M., Rossleigh, M. A., Taylor, D. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8116 · Cited by 153
Brown, J. L., Cao, Z. A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M., Emery, S., McDermott, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0554 · Cited by 154
Vascular endothelial growth factor: Biology and therapeutic applications
Ho, Q. T., & Kuo, C. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.010 · Cited by 182
Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia
Nguyen, Q. D. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.066431 · Cited by 152
Osterlund, P. J., Soveri, L.-M., Isoniemi, H., Poussa, T. A., Alanko, T., & Bono, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.2 · Cited by 153
Targeting apoptosis as an approach for gastrointestinal cancer therapy
Qiao, L., & Yu, W. B. C. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.02.002 · Cited by 154
Seiwert, T. Y., Haraf, D. J., Cohen, E. E. W., Stenson, K. M., Witt, M. E., Dekker, A., Kocherginsky, M., Weichselbaum, R. R., Chen, H. X., & Vokes, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1706 · Cited by 159
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
Zaanan, A., Costes, L., Gauthier, M., Malka, D., Locher, C., Mitry, E., Tougeron, D., Lecomte, T., Gornet, J., Sobhani, I., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq038 · Cited by 160
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 168
Nimeiri, H. S., Oza, A. M., Morgan, R. J., Friberg, G. R., Kasza, K., Faoro, L. N., Salgia, R., Stadler, W. M., Vokes, E. E., & Fleming, G. F. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.009 · Cited by 151
Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
Bokstein, F., Shpigel, S., & Blumenthal, D. T. (2008) · Cancer · doi:10.1002/cncr.23401 · Cited by 158
Sessa, C., Guibal, A., Conte, G. D., & Rüegg, C. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1150 · Cited by 157
Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy
Liu, S.-H., & Cheng, Y. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.01.047 · Cited by 155
Ducreux, M. P., Malka, D., Mendiboure, J., Etienne, P.-L., Texereau, P., Auby, D., Rougier, P. R., Gasmi, M., Castaing, M., Abbas, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70199-1 · Cited by 170
Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond
Mittal, K., Ebos, J. M. L., & Rini, B. I. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.007 · Cited by 161
Wu, W., Yeh, P., Chen, S., Yang, C., Lai, C., & Kuo, H. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.04.018 · Cited by 152
Etienne-Grimaldi, M.-C., Formento, J.-L., Francoual, M., François, E., Formento, P., Renée, N., Laurent-Puig, P., Chazal, M., Benchimol, D., Delpero, J.-R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 151
Shibuya, M. (2006) · Endothelium · doi:10.1080/10623320600697955 · Cited by 171
Pathophysiology of hemophilic arthropathy and potential targets for therapy
Pulles, A. E., Mastbergen, S. C., Schutgens, R. E. G., Lafeber, F. P. J. G., & van Vulpen, L. F. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.032 · Cited by 168
VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)
Peng, F.-W., Liu, D., Zhang, Q., Xu, Y., & Shi, L. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344215 · Cited by 160
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.